ArticleAging2024
Unveiling KLHL23 as a key immune regulator in hepatocellular carcinoma through integrated analysis.
Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PFAS Alter Thyroid Histology and Cellular SignalingJournal of the Endocrine Society · 2026Article
- Advancing liver cancer diagnosis and treatment with multi-omics approaches: a systematic review.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related cancers are characterized by impaired protein homeostasis, where Kelch protein superfamily members have showed accumulating clues as critical regulators. In this paper, the cancerous role of Kelch-like family member 23 (KLHL23) was comprehensively analyzed with TCGA and single cell GEO database across overall 33 cancer types. By multi-omics analysis upon the transcriptomic, genomic, and methylation data, the current study explored the association of KLHL23 with patient survival, gene ontology, tumor-infiltrating lymphocytes, and drug responses. The correlation of copy number variations and methylation with dysregulated expression of KLHL23 were also addressed. Notably, KLHL23 levels correlated with survival in cancers such as hepatocellular carcinoma and low-grade glioma. The study also highlighted how reduced KLHL23 expression is linked to increased immune activity and sensitivity to chemotherapy, suggesting its potential as a biomarker for cancer prognosis and treatment responsiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.